^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ abKinoshita M, Nakamura T, Ihara M, Haraguchi T, Hiraoka Y, Tashiro K, Noda M (juni 2001). "Identification of human endomucin-1 and -2 as membrane-bound O-sialoglycoproteins with anti-adhesive activity". FEBS Letters. 499 (1–2): 121–6. doi:10.1016/S0014-5793(01)02520-0. PMID11418125. S2CID23615506.
^Liu C, Shao ZM, Zhang L, Beatty P, Sartippour M, Lane T, Livingston E, Nguyen M (oktobar 2001). "Human endomucin is an endothelial marker". Biochemical and Biophysical Research Communications. 288 (1): 129–36. doi:10.1006/bbrc.2001.5737. PMID11594763.
^Liu C, et al. (2001). "Human Endomucin Is an Endothelial Marker". Biochemical and Biophysical Research Communications. 288: 129–136. doi:10.1006/bbrc.2001.5737. PMID11594763.
Li G, Miles A, Line A, Rees RC (mart 2004). "Identification of tumour antigens by serological analysis of cDNA expression cloning". Cancer Immunology, Immunotherapy. 53 (3): 139–43. doi:10.1007/s00262-003-0471-y. PMID14722670. S2CID10785466.
Maruyama K, Sugano S (januar 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (oktobar 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.